Direct Measurement of Oligonucleotide Substrate Binding To

Total Page:16

File Type:pdf, Size:1020Kb

Direct Measurement of Oligonucleotide Substrate Binding To Proc. Nati. Acad. Sci. USA Vol. 87, pp. 8187-8191, November 1990 Biochemistry Direct measurement of oligonucleotide substrate binding to wild-type and mutant ribozymes from Tetrahymena (RNA catalysis/gel mobility shift/binding energy/Mg2+ dependence/dissociation constants) ANNA MARIE PYLE, JAMES A. MCSWIGGEN*, AND THOMAS R. CECHt Howard Hughes Medical Institute, Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309-0215 Contributed by Thomas R. Cech, August 8, 1990 ABSTRACT Like protein enzymes, RNA enzymes (ri- 3' end being determined by a Sca I site in the DNA template). bozymes) provide specific binding sites for their substrates. We This ribozyme is 388 nucleotides in length, and G414 has been now show that equilibrium dissociation constants for complexes deleted in order to study reactions in the presence of exoge- between the Tetrahymena ribozyme and its RNA substrates and nous guanosine. The preparation of this ribozyme and its products can be directly measured by electrophoresis in poly- oligonucleotide substrates has been described (2). Oligonucle- acrylamide gels containing divalent cations. Binding is 103- to otide products were transcribed from the same DNA tem- 104-fold tighter (4-5 kcal/mol at 42C) than expected from plates as the substrates, but ATP was omitted to cause the base-pairing interactions alone, implying that tertiary interac- phage T7 RNA polymerase to terminate before transcription of tions also contribute to energetic stabilization. Binding de- the substrate adenine residues. The carrier oligonucleotide of creases with single base changes in the substrate, substitution unrelated sequence (5'-GCGGUAGGUUGCCCN-3', where of deoxyribose sugars, and lower Mg2+ concentration. Ca2+, N is a heterogeneous terminal nucleotide) and carrier tRNA which enables the ribozyme to fold but is unable to mediate were also prepared by transcription with T7 RNA polymerase efficient RNA cleavage, promotes weaker substrate binding and were gifts from M. Fedor and E. Tinkle (University of than Mg2+. This indicates that Mg2& has special roles in both Colorado, Boulder, CO). substrate binding and catalysis. Mutagenesis of a region near Direct Determination of Binding Constants. Ribozyme di- the internal guide sequence disrupts substrate binding, lutions at 2x final concentration were preincubated at 500C whereas binding is not significantly affected by a mutation of for 10 min before mixing with equal volumes of 1.0 nM the guanosine-binding site. This approach should be generally oligonucleotide substrate (S) or product (P). The oligonucle- useful for analysis of ribozyme variants independent of their otide was 5' end-labeled by treatment with calf intestinal catalytic activities. phosphatase followed by polynucleotide kinase and [y_32p]_ ATP (2). Samples were incubated at the indicated tempera- Ribozymes derived from the self-splicing intervening se- tures for 5 min in 50 mM Tris, pH 7.5/0.1 mM EDTA/10 mM quence (IVS) of Tetrahymena rRNA catalyze phosphodiester NaCI/10 mM MgCI2/3% glycerol/0.05% xylene cyanol and bond substrates (1, 2). The mech- then loaded immediately on a polyacrylamide gel (0.4 mm x cleavage ofoligonucleotide 230 mm x 280 mm) running at 10 W. Binding was unaffected anism for this reaction is similar to the first step in self- by the presence of the dye or glycerol in the mixture (as splicing of the pre-rRNA (3). Substrate recognition is medi- determined by substitution with 5% sucrose). The electro- ated by base-pairing interactions between an internal guide phoresis buffer was 100 mM Tris-Hepes, pH 7.5/0.1 mM sequence (IGS) within the ribozyme and a complementary EDTA/10 mM Mg2+. In addition to electrophoresis buffer, substrate (4-6). A schematic of this interaction is shown in the 10% polyacrylamide gel was prepared with a 30:1 weight Fig. 1. Given this model, one should be able to estimate the ratio of acrylamide to N,N'-methylenebisacrylamide. Gels interaction energy by using rules developed for prediction of were run at constant temperature by clamping to a reservoir duplex stability (7-9). For a circular form of the same IVS, fitted with recirculating coils. Quantitation of free oligonu- however, kinetic results suggest that oligonucleotides may cleotide and its complex was performed on an AMBIS bind to the active site with a greater affinity than expected for radioanalytic scanner. Except where noted, binding of sub- simple duplex formation (10, 11). strate and product oligonucleotides was studied in the ab- Nondenaturing gel electrophoresis has been extensively sence of guanosine, in order to prevent strand scission. used for studying nucleic acid-protein associations (12-17). Additional controls were performed to ensure that the gua- Complexes between RNA moieties have also been observed nosine-independent hydrolysis reaction (21) did not cleave in native gels (18-20). Here we show that ribozyme-substrate significant amounts of the substrate under the conditions of complexes are stable in nondenaturing polyacrylamide gels the binding study. The dissociation constant (Kd) obtained containing Mg2' or Ca2+. The ability to partition free and using different ribozyme preparations varied from 0.7 to 1.3 ribozyme-bound RNA substrate makes it possible to quan- nM for GGCCCUCU. Similar day-to-day variation in Kd was titatively study factors contributing to the energetics of observed using different IVS dilutions of the same ribozyme association. preparation. Studies of oligonucleotide binding in the pres- ence of guanosine were performed at room temperature METHODS under the conditions described above except that the elec- RNA Preparation. The L-21 Sca I ribozyme used in this trophoresis buffer was 50 mM Tris/50 mM borate/0.1 mM study is a shortened form of the Tetrahymena thermophila EDTA, pH 8.3/0.5 mM guanosine/10 mM MgCl2. pre-rRNA IVS, lacking the first 21 and last 5 nucleotides (the Abbreviations: IVS, intervening sequence; IGS, internal guide se- quence. The publication costs of this article were defrayed in part by page charge *Present address: United States Biochemical Corporation, Cleve- payment. This article must therefore be hereby marked "advertisement" land, OH 44122. in accordance with 18 U.S.C. §1734 solely to indicate this fact. tTo whom reprint requests should be addressed. 8187 Downloaded by guest on September 30, 2021 8188 Biochemistry: Pyle et al. Proc. Natl. Acad. Sci. USA 87 (1990) G-binding site Kd + GGCCCUCUAAAAA A A A "matched" E-S complex free ribozyme substrate (E) (S) rG '-) GA5 Kd GGq9qyw9t + GGCCCUCU A/ A cA "matched" E- P complex free ribozyme product (E) (P) FIG. 1. Schematic of the interaction between the L-21 Sca I ribozyme and its "matched" substrate and product. In the E-S complex, base-pairingjoins the substrate to a portion ofthe IGS (3'-GGGAGG-5') to form helix P1. After ribozyme-catalyzed cleavage, similar interactions persist in the E'P complex. The guanosine-binding site is depicted above the P1 helix, where it is poised to effect scission of the substrate U-A bond. Two of the three italicized adenine residues are deleted in the J1/2-2A variant of the ribozyme. Determination of Binding by Competition. The association tration ofsubstrate (0.05-1 nM), the volume ofsample loaded of GGCCCGCU, GGCCCGCUA5, and d(GGCCCUCU) to on the gel, or the electrophoresis time. Carrier RNA mole- the ribozyme was studied by competition with the radiola- cules, including tRNA and an unstructured oligonucleotide of beled probe 32P-GGCCCUCU. The validity of the competi- unrelated sequence (both at 400 nM in nucleotides), did not tion assay was verified in two ways. Unlabeled GGCCCUCU change the Kd ofCCCUCU and therefore did not compete for was found to compete with 32P-GGCCCUCU in binding to the binding site. This confirms that complementarity between the ribozyme at 250C. A calculated Kd for the inhibitor was the active site and oligonucleotides is essential for associa- found to be 1.5 nM. Second, the binding of 32P-GGCCCGCU tion. was studied directly at several temperatures and found to be Equilibrium Dissociation Constants of Oligonucleotide- only a factor of 3 weaker than that determined by competi- Ribozyme Complexes. The dissociation constant of GGC- tion. The competitive Kd determination is more reliable due CCUCU obtained by inspection of the gel midpoint (Fig. 2A) to smearing of the relatively unstable 32P-GGCCCGCU- or the fit to a theoretical binding curve (Fig. 2B) is =1 nM at ribozyme complex in the gel, which artifically lowers the 250C and 42TC. This value corresponds to a binding free observed Kd. energy of -12.2 (250C) or -12.9 (420C) kcal/mol, which is Free Energy Calculations. The observed free energies were =0.4 kcal/mol greater than the energy calculated by consid- determined as AG' = -RT ln(l/Kd), where R = 0.00198 ering base-pairing alone at 250C and 4.0 kcal/mol greater at kcal-mol-1K-1 and T is in kelvins. The calculated free 420C. energies were determined by AGO = AHM - TAS0 using AH0 The structure of RNA substrates and products was varied and ASO values from refs. 8 and 9. The terminal A-G in order to learn more about specific binding requirements. A mismatch and the terminal G-U pair were included in the single base substitution at a position three nucleotides from calculation. the 3' end of the product adversely affects binding to the ribozyme. This is shown by comparison of 1 with 4 and 2 with 5 in Table 1. However, the binding remains tighter than that RESULTS calculated for a simple mismatched helix, 4.5 kcal/mol of Method for Direct Determination of Binding Constants. The extra binding energy at 250C, and 5.5 kcal/mol at 420C for 4. oligonucleotide GGCCCUCU, which forms a "matched" There is little difference in the Kd of reaction substrates and duplex with the guide sequence of the ribozyme, represents their corresponding products.
Recommended publications
  • RNA Pull-Down Procedure to Identify RNA Targets of a Long Non-Coding
    RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA Manon Torres, Denis Becquet, Séverine Guillen, Bénédicte Boyer, Mathias Moreno, Marie-Pierre Blanchard, Jean-Louis Franc, Anne-Marie François-Bellan To cite this version: Manon Torres, Denis Becquet, Séverine Guillen, Bénédicte Boyer, Mathias Moreno, et al.. RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA. Journal of visualized experiments : JoVE, JoVE, 2018, 10.3791/57379. hal-02093065 HAL Id: hal-02093065 https://hal-amu.archives-ouvertes.fr/hal-02093065 Submitted on 20 Dec 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License Journal of Visualized Experiments www.jove.com Video Article RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA Manon Torres1, Denis Becquet1, Séverine Guillen1, Bénédicte Boyer1, Mathias Moreno1, Marie-Pierre Blanchard2, Jean-Louis Franc1, Anne- Marie François-Bellan1 1 CNRS, CRN2M-UMR7286, Faculté
    [Show full text]
  • Advances in Oligonucleotide Drug Delivery
    REVIEWS Advances in oligonucleotide drug delivery Thomas C. Roberts 1,2 ✉ , Robert Langer 3 and Matthew J. A. Wood 1,2 ✉ Abstract | Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing. As such, these molecules have potential therapeutic applications for myriad indications, with several oligonucleotide drugs recently gaining approval. However, despite recent technological advances, achieving efficient oligonucleotide delivery, particularly to extrahepatic tissues, remains a major translational limitation. Here, we provide an overview of oligonucleotide-based drug platforms, focusing on key approaches — including chemical modification, bioconjugation and the use of nanocarriers — which aim to address the delivery challenge. Oligonucleotides are nucleic acid polymers with the In addition to their ability to recognize specific tar- potential to treat or manage a wide range of diseases. get sequences via complementary base pairing, nucleic Although the majority of oligonucleotide therapeutics acids can also interact with proteins through the for- have focused on gene silencing, other strategies are being mation of three-dimensional secondary structures — a pursued, including splice modulation and gene activa- property that is also being exploited therapeutically. For tion, expanding the range of possible targets beyond example, nucleic acid aptamers are structured
    [Show full text]
  • Guide for Morpholino Users: Toward Therapeutics
    Open Access Journal of Drug Discovery, Development and Delivery Special Article - Antisense Drug Research and Development Guide for Morpholino Users: Toward Therapeutics Moulton JD* Gene Tools, LLC, USA Abstract *Corresponding author: Moulton JD, Gene Tools, Morpholino oligos are uncharged molecules for blocking sites on RNA. They LLC, 1001 Summerton Way, Philomath, Oregon 97370, are specific, soluble, non-toxic, stable, and effective antisense reagents suitable USA for development as therapeutics and currently in clinical trials. They are very versatile, targeting a wide range of RNA targets for outcomes such as blocking Received: January 28, 2016; Accepted: April 29, 2016; translation, modifying splicing of pre-mRNA, inhibiting miRNA maturation and Published: May 03, 2016 activity, as well as less common biological targets and diagnostic applications. Solutions have been developed for delivery into a range of cultured cells, embryos and adult animals; with development of a non-toxic and effective system for systemic delivery, Morpholinos have potential for broad therapeutic development targeting pathogens and genetic disorders. Keywords: Splicing; Duchenne muscular dystrophy; Phosphorodiamidate morpholino oligos; Internal ribosome entry site; Nonsense-mediated decay Morpholinos: Research Applications, the transcript from miRNA regulation; Therapeutic Promise • Block regulatory proteins from binding to RNA, shifting Morpholino oligos bind to complementary sequences of RNA alternative splicing; and get in the way of processes. Morpholino oligos are commonly • Block association of RNAs with cytoskeletal motor protein used to prevent a particular protein from being made in an organism complexes, preventing RNA translocation; or cell culture. Morpholinos are not the only tool used for this: a protein’s synthesis can be inhibited by altering DNA to make a null • Inhibit poly-A tailing of pre-mRNA; mutant (called a gene knockout) or by interrupting processes on RNA • Trigger frame shifts at slippery sequences; (called a gene knockdown).
    [Show full text]
  • Recent Advances in Oligonucleotide Therapeutics in Oncology
    International Journal of Molecular Sciences Review Recent Advances in Oligonucleotide Therapeutics in Oncology Haoyu Xiong 1, Rakesh N. Veedu 2,3 and Sarah D. Diermeier 1,* 1 Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand; [email protected] 2 Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia; [email protected] 3 Perron Institute for Neurological and Translational Science, Perth 6009, Australia * Correspondence: [email protected] Abstract: Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges. Keywords: antisense oligonucleotides; siRNA; aptamers; DNAzymes; cancers Citation: Xiong, H.; Veedu, R.N.; 1. Introduction Diermeier, S.D. Recent Advances in Oligonucleotide Therapeutics in According to the Global Cancer Statistics 2018, there were more than 18 million new Oncology. Int. J. Mol. Sci. 2021, 22, cancer cases and 9.6 million deaths caused by cancer in 2018 [1].
    [Show full text]
  • Locked Nucleic Acid: Modality, Diversity, and Drug Discovery
    Downloaded from orbit.dtu.dk on: Sep 23, 2021 Locked nucleic acid: modality, diversity, and drug discovery Hagedorn, Peter H.; Persson, Robert; Funder, Erik D.; Albæk, Nanna; Diemer, Sanna L.; Hansen, Dennis J.; Møller, Marianne R; Papargyri, Natalia; Christiansen, Helle; Hansen, Bo R. Total number of authors: 13 Published in: Drug Discovery Today Link to article, DOI: 10.1016/j.drudis.2017.09.018 Publication date: 2018 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Hagedorn, P. H., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller, M. R., Papargyri, N., Christiansen, H., Hansen, B. R., Hansen, H. F., Jensen, M. A., & Koch, T. (2018). Locked nucleic acid: modality, diversity, and drug discovery. Drug Discovery Today, 23(1), 101-114. https://doi.org/10.1016/j.drudis.2017.09.018 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Ribozyme-Catalyzed Primer Extension by Trinucleotides: a Model for the RNA-Catalyzed Replication of RNA+ Jennifer A
    Biochemistry 1993, 32, 21 11-21 15 2111 Ribozyme-Catalyzed Primer Extension by Trinucleotides: A Model for the RNA-Catalyzed Replication of RNA+ Jennifer A. Doudna,t Nassim Usman,$ and Jack W. Szostak’ Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 021 I4 Received October 2. 1992; Revised Manuscript Received November 25, I992 ABSTRACT: The existence of RNA enzymes that catalyze phosphodiester transfer reactions suggests that RNA-catalyzed RNA replication might be possible. Indeed, it has been shown that the Tetrahymena and sunY self-splicing introns will catalyze the template-directed ligation of RNA oligonucleotides (Doudna et al., 1989, 1991). We have sought to develop a more general RNA replication system in which arbitrary template sequences could be copied by the assembly of a limited set of short oligonucleotides. Here we examine the use of tetranucleotides as substrates for a primer-extension rea ion in which the 5’-nucleoside of the tetranucleotide is the leaving group, and the primer is extended by the remaining three nucleotides. When the 5’-nucleoside is guanosine, the reaction is quite efficient, but a number of competing side reactions occur, in which inappropriate guanosine residues in the primer or the template occupy the guanosine binding site of the ribozyme. We have blocked these side reactions by using the guanosine analogue 2-aminopurine riboside (2AP) as the leaving group, in a reaction catalyzed by a mutant sunYribozyme that binds efficiently to 2AP and not to guanosine. We have begun to address the issue of the fidelity of the primer-extension reaction by measuring reaction rates with a number of different triplet/template combinations.
    [Show full text]
  • Exponential Growth by Cross-Catalytic Cleavage of Deoxyribozymogens
    Exponential growth by cross-catalytic cleavage of deoxyribozymogens Matthew Levy and Andrew D. Ellington* Department of Chemistry and Biochemistry, Institute for Cell and Molecular Biology, University of Texas, Austin, TX 78712 Edited by Gerald F. Joyce, The Scripps Research Institute, La Jolla, CA, and approved April 10, 2003 (received for review January 9, 2003) We have designed an autocatalytic cycle based on the highly efficient 10–23 RNA-cleaving deoxyribozyme that is capable of exponential amplification of catalysis. In this system, complemen- tary 10–23 variants were inactivated by circularization, creating deoxyribozymogens. Upon linearization, the enzymes can act on their complements, creating a cascade in which linearized species accumulate exponentially. Seeding the system with a pool of linear catalysts resulted not only in amplification of function but in sequence selection and represents an in vitro selection experiment conducted in the absence of any protein enzymes. emonstrating molecular self-amplification is essential for Dunderstanding origins and can potentially foment biotech- nology applications, especially in diagnostics. In modern biology, molecular replication is dominated by cycles in which nucleic acids encode and are replicated by protein enzymes. However, the discovery and subsequent engineering of nucleic acid cata- lysts raises the possibility that nucleic acid-based, autocatalytic cycles might be designed. In this regard, von Kiedrowski (1) and Zielinski and Orgel (2) showed that oligonucleotide palindromes can serve as templates for the ligation of shorter oligonucleotide substrates, and thus for their own reproduction. Variations on this theme have led to proof that short oligonucleotide templates are capable of semi- Fig. 1. Design of linear and circular 10–23 deoxyribozymes.
    [Show full text]
  • Catalytic DNA: Scope, Applications, and Biochemistry of Deoxyribozymes
    Review Catalytic DNA: Scope, Applications, and Biochemistry of Deoxyribozymes 1, ,@ Scott K. Silverman * The discovery of natural RNA enzymes (ribozymes) prompted the pursuit of Trends artificial DNA enzymes (deoxyribozymes) by in vitro selection methods. A key As a synthetic catalyst identified by in motivation is the conceptual and practical advantages of DNA relative to pro- vitro selection, single-stranded DNA has many advantages over proteins teins and RNA. Early studies focused on RNA-cleaving deoxyribozymes, and and RNA. The growing reaction scope more recent experiments have expanded the breadth of catalytic DNA to many of deoxyribozymes is increasing our fi other reactions. Including modi ed nucleotides has the potential to widen the fundamental understanding of biocata- lysis, enabling applications in chemistry scope of DNA enzymes even further. Practical applications of deoxyribozymes and biology. include their use as sensors for metal ions and small molecules. Structural fi studies of deoxyribozymes are only now beginning; mechanistic experiments Including modi ed DNA nucleotides enhances the catalytic ability of will surely follow. Following the first report 21 years ago, the field of deoxy- deoxyribozymes. Several approaches ribozymes has promise for both fundamental and applied advances in chemis- for this purpose are being evaluated. try, biology, and other disciplines. Investigators are pursuing practical applications for deoxyribozymes, such Nucleic Acids as Catalysts as in vivo mRNA cleavage and sensing Nature has evolved a wide range of protein enzymes for biological catalysis. The notion that of metal ions and small molecules. biomolecules other than proteins can be catalysts was largely disregarded until the early 1980s, when the enzymatic abilities of natural RNA catalysts (ribozymes; see Glossary) were discov- High-resolution structural analysis of deoxyribozymes is a new field; the first ered [1,2].
    [Show full text]
  • Multifunctional Delivery Systems for Peptide Nucleic Acids
    pharmaceuticals Review Multifunctional Delivery Systems for Peptide Nucleic Acids Stefano Volpi , Umberto Cancelli, Martina Neri and Roberto Corradini * Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy; [email protected] (S.V.); [email protected] (U.C.); [email protected] (M.N.) * Correspondence: [email protected]; Tel.: +39-0521-905410 Abstract: The number of applications of peptide nucleic acids (PNAs)—oligonucleotide analogs with a polyamide backbone—is continuously increasing in both in vitro and cellular systems and, parallel to this, delivery systems able to bring PNAs to their targets have been developed. This review is intended to give to the readers an overview on the available carriers for these oligonucleotide mimics, with a particular emphasis on newly developed multi-component- and multifunctional vehicles which boosted PNA research in recent years. The following approaches will be discussed: (a) conjugation with carrier molecules and peptides; (b) liposome formulations; (c) polymer nanopar- ticles; (d) inorganic porous nanoparticles; (e) carbon based nanocarriers; and (f) self-assembled and supramolecular systems. New therapeutic strategies enabled by the combination of PNA and proper delivery systems are discussed. Keywords: peptide nucleic acids; delivery; nanoparticles; conjugates; multifunctional systems 1. Introduction 1.1. Peptide Nucleic Acids and Their Uses Peptide nucleic acids (PNAs, Figure1) are DNA analogues in which the sugar- Citation: Volpi, S.; Cancelli, U.; phosphate units connecting the nucleobases are replaced by N-(2-aminoethyl)glycine Neri, M.; Corradini, R. moieties [1]. These molecules are excellent binding partners for cognate DNA and RNA Multifunctional Delivery Systems for strands, being able to exploit both the canonical Watson–Crick (WC) base pairing to form Peptide Nucleic Acids.
    [Show full text]
  • Designing Chemically Modified Oligonucleotides for Targeted Gene
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Chemistry & Biology Review Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing Glen F. Deleavey1,* and Masad J. Damha1,* 1Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montre´ al, QC H3A 0B8, Canada *Correspondence: [email protected] (G.F.D.), [email protected] (M.J.D.) http://dx.doi.org/10.1016/j.chembiol.2012.07.011 Oligonucleotides (ONs), and their chemically modified mimics, are now routinely used in the laboratory as a means to control the expression of fundamentally interesting or therapeutically relevant genes. ONs are also under active investigation in the clinic, with many expressing cautious optimism that at least some ON-based therapies will succeed in the coming years. In this review, we will discuss several classes of ONs used for controlling gene expression, with an emphasis on antisense ONs (AONs), small interfering RNAs (siRNAs), and microRNA-targeting ONs (anti-miRNAs). This review provides a current and detailed account of ON chemical modification strategies for the optimization of biological activity and therapeutic application, while clarifying the biological pathways, chemical properties, benefits, and limitations of oligo- nucleotide analogs used in nucleic acids research. The concept of using synthetic oligonucleotides (ONs) to control stability, (2) low efficiency of intracellular delivery to targets cells the expression of specific genes dates back to the late 1970s, or tissues, and (3) the potential for ‘‘off-target’’ gene silenc- when Zamecnik and Stephenson first demonstrated targeted ing, immunostimulation, and other side effects. Fortunately, in gene silencing using a short synthetic oligonucleotide (Zamecnik attempts to overcome the therapeutically limiting features of and Stephenson, 1978; Stephenson and Zamecnik, 1978).
    [Show full text]
  • The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey
    biomedicines Review The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey Sudhir Agrawal 1,2 1 ARNAY Sciences LLC, Shrewsbury, MA 01545, USA; [email protected] or [email protected] 2 Department of Medicine, University of Massachusetts Medical School, 55 N Lake Ave, Worcester, MA 01655, USA Abstract: Over the last four decades, tremendous progress has been made in use of synthetic oligonu- cleotides as therapeutics. This has been possible largely by introducing chemical modifications to provide drug like properties to oligonucleotides. In this article I have summarized twists and turns on use of chemical modifications and their road to success and highlight areas of future directions. Keywords: oligonucleotide; therapeutic; antisense; medicinal chemistry; structure activity relationship 1. Introduction Today RNA therapeutics are a clinical reality with approved drugs that employ a variety of different mechanisms of action (reviewed recently in [1]). However, here I would like to take you back to the beginnings of antisense and show you how the evolution of antisense chemistry played an essential role in turning oligonucleotides into therapeutics. I Citation: Agrawal, S. The Evolution would like to dedicate this chapter to Paul Zamecnik (1912–2009), my mentor, friend, and of Antisense Oligonucleotide colleague who introduced me to the field of antisense therapeutics and who first dreamed Chemistry—A Personal Journey. of using antisense oligonucleotides as therapeutics [2]. To achieve his dream, we had to Biomedicines 2021, 9, 503. improve antisense oligonucleotide chemistry, understand how the chemistry, structure, and https://doi.org/10.3390/ sequence influences antisense oligonucleotide function, and how the immune system deals biomedicines9050503 with exogenous nucleic acids.
    [Show full text]
  • Oligonucleotide Clamps Arrest DNA Synthesis on a Single-Stranded DNA Target (Triplex/Psoralen/Replication) CARINE GIOVANNANGELI*, NGUYEN T
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 10013-10017, November 1993 Biochemistry Oligonucleotide clamps arrest DNA synthesis on a single-stranded DNA target (triplex/psoralen/replication) CARINE GIOVANNANGELI*, NGUYEN T. THUONGt, AND CLAUDE HtLtNE* *Laboratoire de Biophysique, Institut National de la Sante et de la Recherche Mddicale Unite 201, Centre National de la Recherche Scientifique Unit6 Associde 481, Museum National d'Histoire Naturelle, 43, Rue Cuvier, 75231 Paris Cedex 05, France; and tCentre de Biophysique Moldculaire, 45071 Orleans Cedex 02, France Communicated by I. Tinoco, June 1, 1993 ABSTRACT Triple helices can be formed on single- bound to a polypurine sequence (5, 6). Here we show that stranded oligopurine target sequences by composite oligonu- different linkers can be used to tether the Watson-Crick and cleotides consisting oftwo oligonucleotides covalently linked by Hoogsteen base-pair-forming portions of the OLO without either a hexaethylene glycol linker or an oligonucleotide se- loss of stability of the resultant triple helix. A psoralen quence. The first oligomer forms Watson-Crick base pairs with derivative attached to the 5' end of the OLO may be the target, while the second oligomer engages in Hoogsteen base crosslinked to its target sequence in such a way that the three pairing, thereby acting as a molecular clamp. The triple-helical strands of the resultant triplex become covalently linked to complex formed by such an oligonucleotide clamp, or "oligo- one another. These complexes act as strong stop signals, nucleotide4oop-oligonucleotide" (OLO), is more stable than blocking chain elongation during replication. This inhibition either the corresponding trimolecular triple helix or the double is much more efficient than that obtained with an antisense helix formed upon binding of the oligopyrimidine complement oligonucleotide carrying a reactive psoralen group.
    [Show full text]